These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25884438)

  • 21. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
    Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
    Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Furan and p-xylene as candidate biomarkers for prostate cancer.
    Jiménez-Pacheco A; Salinero-Bachiller M; Iribar MC; López-Luque A; Miján-Ortiz JL; Peinado JM
    Urol Oncol; 2018 May; 36(5):243.e21-243.e27. PubMed ID: 29395956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.
    Adeola HA; Soares NC; Paccez JD; Kaestner L; Blackburn JM; Zerbini LF
    Proteomics Clin Appl; 2015 Jun; 9(5-6):597-609. PubMed ID: 25708745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.
    Guo J; Yang J; Zhang X; Feng X; Zhang H; Chen L; Johnson H; Persson JL; Xiao K
    Anticancer Res; 2018 Mar; 38(3):1471-1477. PubMed ID: 29491074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
    Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
    Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals.
    Moradi Sardareh H; Goodarzi MT; Yadegar-Azari R; Poorolajal J; Mousavi-Bahar SH; Saidijam M
    Urol J; 2014 Nov; 11(6):1952-8. PubMed ID: 25433473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
    He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
    Front Immunol; 2022; 13():998447. PubMed ID: 36685547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
    Shen M; Chen W; Yu K; Chen Z; Zhou W; Lin X; Weng Z; Li C; Wu X; Tao Z
    Exp Mol Pathol; 2011 Feb; 90(1):97-100. PubMed ID: 20970419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
    Su Z; Wang G; Li L
    Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
    Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
    BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of ferritin with prostate cancer.
    Su Q; Lei T; Zhang M
    J BUON; 2017; 22(3):766-770. PubMed ID: 28730787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of multiple biomarkers for a molecular diagnosis of prostate cancer.
    Landers KA; Burger MJ; Tebay MA; Purdie DM; Scells B; Samaratunga H; Lavin MF; Gardiner RA
    Int J Cancer; 2005 May; 114(6):950-6. PubMed ID: 15609297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
    Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer.
    Bayat H; Narouie B; Ziaee SM; Mowla SJ
    Prostate; 2018 Aug; 78(11):812-818. PubMed ID: 29671889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen in urine.
    Breul J; Pickl U; Hartung R
    Eur Urol; 1994; 26(1):18-21. PubMed ID: 7523129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.
    Ma W; Diep K; Fritsche HA; Shore N; Albitar M
    Genet Test Mol Biomarkers; 2014 Mar; 18(3):156-63. PubMed ID: 24512523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.